Last reviewed · How we verify
Intravenous Ascorbate
Intravenous ascorbate (vitamin C) acts as a pro-oxidant at high concentrations to generate reactive oxygen species that selectively kill cancer cells while supporting immune function.
Intravenous ascorbate (vitamin C) acts as a pro-oxidant at high concentrations to generate reactive oxygen species that selectively kill cancer cells while supporting immune function. Used for Advanced or metastatic cancer (various solid tumors), Cancer adjunctive therapy in combination with conventional chemotherapy.
At a glance
| Generic name | Intravenous Ascorbate |
|---|---|
| Also known as | Ascorbic Acid Injection |
| Sponsor | University of Malaya |
| Drug class | Antioxidant/Pro-oxidant agent |
| Target | Reactive oxygen species generation; multiple indirect targets |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
At pharmacological doses achieved through intravenous administration, ascorbate generates hydrogen peroxide and other reactive oxygen species that induce oxidative stress in tumor cells, triggering apoptosis. Simultaneously, ascorbate supports immune cell function and may enhance the efficacy of conventional chemotherapy or immunotherapy through multiple mechanisms including collagen synthesis and antioxidant support in normal tissues.
Approved indications
- Advanced or metastatic cancer (various solid tumors)
- Cancer adjunctive therapy in combination with conventional chemotherapy
Common side effects
- Infusion site reactions
- Nausea and vomiting
- Fatigue
- Hyperglycemia (in susceptible patients)
- Kidney stone risk (chronic use)
Key clinical trials
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE1)
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (PHASE1)
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme (PHASE2)
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (PHASE1)
- Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Ascorbate CI brief — competitive landscape report
- Intravenous Ascorbate updates RSS · CI watch RSS
- University of Malaya portfolio CI